4//SEC Filing
Funicular Fund, LP 4
Accession 0000921895-22-001792
CIK 0000907654other
Filed
May 24, 8:00 PM ET
Accepted
May 25, 5:12 PM ET
Size
12.9 KB
Accession
0000921895-22-001792
Insider Transaction Report
Form 4
Funicular Fund, LP
Other
Transactions
- Purchase
Common Stock
2022-05-25$2.32/sh+64,851$150,740→ 2,580,452 total - Purchase
Common Stock
2022-05-23$2.29/sh+2,301$5,281→ 2,497,491 total - Purchase
Common Stock
2022-05-24$2.29/sh+18,110$41,383→ 2,515,601 total
Holdings
- 14,500
Put Option (obligation to buy)
Exercise: $2.50From: 2022-12-16Exp: 2022-12-16→ Common Stock (1,450,000 underlying)
Ma-Weaver Jacob
Other
Transactions
- Purchase
Common Stock
2022-05-25$2.32/sh+64,851$150,740→ 2,580,452 total - Purchase
Common Stock
2022-05-23$2.29/sh+2,301$5,281→ 2,497,491 total - Purchase
Common Stock
2022-05-24$2.29/sh+18,110$41,383→ 2,515,601 total
Holdings
- 14,500
Put Option (obligation to buy)
Exercise: $2.50From: 2022-12-16Exp: 2022-12-16→ Common Stock (1,450,000 underlying)
Footnotes (4)
- [F1]This Form 4 is filed by the Funicular Fund, LP (the "Fund") and Jacob Ma-Weaver (the "Reporting Persons"). The Reporting Persons and Cable Car Capital LLC ("Cable Car") may be deemed to be a member of a Section 13(d) group that may be deemed to collectively beneficially own more than 10% of the Issuer's outstanding shares of Common Stock (the "Shares"). Each of the Reporting Persons and Cable Car disclaim beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- [F2]Represents securities directly owned by the Fund. Cable Car, as the general partner of the Fund, may be deemed to beneficially own the securities directly owned by the Fund. Mr. Ma-Weaver, as the Managing Member of Cable Car, may be deemed to beneficially own the securities directly owned by the Fund.
- [F3]Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $2.2850 to $2.2950, inclusive of brokerage commissions. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
- [F4]Represents a weighted average price. These Shares were purchased in multiple transactions at prices ranging from $2.2550 to $2.3450, inclusive of brokerage commissions. The Reporting Persons undertake to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Shares purchased at each separate price within the range set forth in this footnote.
Documents
Issuer
ARCA biopharma, Inc.
CIK 0000907654
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001752618
Filing Metadata
- Form type
- 4
- Filed
- May 24, 8:00 PM ET
- Accepted
- May 25, 5:12 PM ET
- Size
- 12.9 KB